{
    "clinical_study": {
        "@rank": "15028", 
        "arm_group": [
            {
                "arm_group_label": "OC000459 Tablets", 
                "arm_group_type": "Experimental", 
                "description": "50 mg orally once a day"
            }, 
            {
                "arm_group_label": "Placebo Tablets", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Orally once a day"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether OC000459 is in reducing disease severity\n      and preventing flares in people with moderate to severe atopic dermatitis (AD)."
        }, 
        "brief_title": "Effect of OC000459 on Moderate to Severe Atopic Dermatitis", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will include patients with a Th2 high eosinophilic phenotype who typically have\n      more severe disease and are prone to flare."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Atopic dermatitis as defined by a score of at least 9 on the Nottingham Eczema\n             Severity Score, stratified into moderate (score 9 to 11 inclusive) and severe (score\n             12 to 15 inclusive) disease.\n\n          2. Fully documented history of the use of topical corticosteroids (TCS) and/or topical\n             calcineurin inhibitors (TCI). Subjects without a fully documented history will be\n             excluded from the study.\n\n          3. Male and female subjects with moderate to severe atopic dermatitis treated with by\n             TCS and/or TCI (with or without emollients) at the time of screening and over the\n             previous month.\n\n          4. Subjects must have had at least 1 AD flare in the previous 6 months.\n\n        Exclusion Criteria:\n\n          1. Receipt of any forbidden medication including over the counter preparations and\n             herbal medicines within 14 days of the first dosing day with the exception of\n             paracetamol up to a maximum of 2g daily.\n\n          2. Use of systemic steroids within 4 weeks of the screening visit, light therapy or\n             immunosuppressants within 2 months of the screening visit.\n\n          3. Use of NSAIDs.\n\n          4. Subjects initially diagnosed with AD aged 2 years or over will be excluded unless\n             they have either coexisting or a history of asthma and/or allergic\n             rhinoconjunctivitis.\n\n          5. Subjects with contact dermatitis will be excluded.\n\n          6. Subjects with acute skin infection or acute disease flares. Subjects with active\n             flares during the screening to randomisation period (visits 1 to 2) may be managed\n             according to normal clinical practice and be rescreened once their flares are no\n             longer active.\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "48 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002208", 
            "org_study_id": "OC000459/017/13"
        }, 
        "intervention": {
            "arm_group_label": [
                "OC000459 Tablets", 
                "Placebo Tablets"
            ], 
            "description": "None", 
            "intervention_name": "OC000459", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "contact": {
                "last_name": "Michael Cork"
            }, 
            "facility": {
                "address": {
                    "city": "Sheffield", 
                    "country": "United Kingdom"
                }, 
                "name": "Professor Michael Cork"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Study of the Effect of OC000459 on Signs and Symptoms in Subjects With Moderate to Severe Atopic Dermatitis: A Randomised Double Blind Placebo Controlled Parallel Group Study", 
        "overall_contact": {
            "last_name": "Patrick Kalscheuer", 
            "phone": "+49 221 5999247"
        }, 
        "overall_contact_backup": {
            "last_name": "Heidrun Budde", 
            "phone": "+49 221 5999240"
        }, 
        "overall_official": [
            {
                "affiliation": "Universit\u00e4tsklinik Bonn Klinik und Poliklinik f\u00fcr Dermatologie und Allergologie", 
                "last_name": "Thomas Bieber, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Department of Infection and Immunity, The University of Sheffield Medical School", 
                "last_name": "Michael Cork, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Skin and Allergy Hospital, Helsinki University Central Hospital", 
                "last_name": "Sakari Reitamo, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "H\u00f4pital Larrey - CHU TOULOUSE Service de Dermatologie", 
                "last_name": "Carle Paul, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universit\u00e4tsklinikum Schleswig-Holstein,Campus Kiel", 
                "last_name": "Regina Folster-Holst", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Klinikum der Johann-Wolfgang-Goethe Universit\u00e4t,Frankfurt", 
                "last_name": "Roland Kaufmann", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universit\u00e4tsklinikum Leipzig", 
                "last_name": "Jan Simon", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "MENSINGDERMA Research Hamburg", 
                "last_name": "Swarna Ekanayake-Bohlig", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CentroDerm GmbH, Heinz-Fangman-Strasse 57, Wuppertal", 
                "last_name": "Thomas Dirschka", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Klinik f\u00fcr Dermatologie; Charit\u00e9 - Campus Mitte, Luisenstra\u00dfe 2;10117-Berlin", 
                "last_name": "Margitta Worm", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dermatology Department, Royal Free Hospital, Pond Street,London NW3 2QG", 
                "last_name": "Malcolm Rustin", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "TYKS T-sairaala, Allergiayksikk\u00f6 TA2,  H\u00e4meentie 11, 20520 Turku, Finland", 
                "last_name": "Kaija Lammintausta", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "H\u00f4pital saint Andr\u00e9 - CHU BORDEAUX Service de Dermatologie, 1 rue Jean Burguet, 33075-Bordeaux,", 
                "last_name": "Alain Taieb", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Klinik und Poliklinik f\u00fcr Dermatologie & Allergologie der LMU M\u00fcnchen", 
                "last_name": "Andreas Wollenberg", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universit\u00e4tsklinikum D\u00fcsseldorf, Hautklinik,", 
                "last_name": "Bernhard Homey", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universit\u00e4tstklinikum M\u00fcnster; Klinik & Poliklinik f\u00fcr Hautkrankheiten;", 
                "last_name": "Athanasios Tsianakas", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Harrogate & District NHS Foundation Trust, Lancaster Park Road,HG2 7SX", 
                "last_name": "Alison Layton", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dept Dermatology & Wound Healing,3rd floor, Glamorgan House,  University Hospital of Wales, Heath Park, Cardiff,CF14 4XN", 
                "last_name": "Vincent Piguet", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Hospitalier Lyon Sud - Unit\u00e9 de Recherche en Immunologie, Secteur 1 - Pavillon 1 K 165, chemin du Grand Revoyet,69495-Pierre Benite Cedex, France", 
                "last_name": "Catherine Goujon", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Austria: Austrian Medicines and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in Eczema Area and Severity Index  (EASI) compared to placebo", 
            "safety_issue": "No", 
            "time_frame": "Baseline, and every 2 weeks for 14 weeks and every 4 weeks for 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002208"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Flares (number of flares, time to first flare, time to resolution of flare, number of flare-free days)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, and every 2 weeks for 14 weeks and every 4 weeks for 12 weeks"
        }, 
        "source": "Atopix Therapeutics, Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Atopix Therapeutics, Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}